BiotechTube

XL765 (SAR245409) + Temozolomide

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mixed Gliomas

Conditions

Mixed Gliomas, Malignant Gliomas, Glioblastoma Multiforme

Trial Timeline

Aug 1, 2008 → Feb 1, 2013

NCT ID
NCT00704080

About XL765 (SAR245409) + Temozolomide

XL765 (SAR245409) + Temozolomide is a phase 1 stage product being developed by Sanofi for Mixed Gliomas. The current trial status is completed. This product is registered under clinical trial identifier NCT00704080. Target conditions include Mixed Gliomas, Malignant Gliomas, Glioblastoma Multiforme.

What happened to similar drugs?

2 of 17 similar drugs in Mixed Gliomas were approved

Approved (2) Terminated (2) Active (13)
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅TegaserodNovartisApproved
🔄olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
🔄Lurasidone + PlaceboSumitomo PharmaPhase 3
🔄MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
🔄Inclisiran + Matching Placebo for InclisiranNovartisPhase 3
🔄FluvastatinNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00704080Phase 1Completed

Competing Products

20 competing products in Mixed Gliomas

See all competitors
ProductCompanyStageHype Score
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
40
Lurasidone + PlaceboSumitomo PharmaPhase 3
40
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
40
Inclisiran + Matching Placebo for InclisiranNovartisPhase 3
40
TegaserodNovartisApproved
43
FluvastatinNovartisPhase 3
40
Atorvastatin + EvolocumabAmgenPhase 3
40
Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to AtorvastatinAmgenPhase 3
40
Blinatumomab in combination with donor lymphocyte infusionAmgenPhase 2
27
Evolocumab + AtorvastatinAmgenPhase 3
40
Evolocumab + Standard of CareAmgenPhase 3
40
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
32
Bococizumab + PlaceboPfizerPhase 3
32
tafamidisPfizerPre-clinical
26
IBI306 + placebo + placebo + IBI306Innovent BiologicsPhase 3
47
KarXTBristol Myers SquibbPhase 3
47
KarXTBristol Myers SquibbPhase 3
47
Gemcitabine + OxaliplatinSanofiPhase 2
35
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40